AMGN
$192.45
Amgen
$.90
.47%
AMGN
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $3.25
Revenue:  $5.88 Bil
Tuesday
Jan 29
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, October 30, 2018

What do you expect when AMGN reports earnings?
Beat
Meet
Miss

Where is AMGN's stock price going from here?
Up
Flat
Down
Stock chart of AMGN
Analysts
Summary of analysts' recommendations for AMGN
Score
Grade
Pivots
Resistance
$197.69
$196.26
$193.90

$192.47

Support
$190.11
$188.68
$186.32
Tweet
Growth
Description
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Peers
BiogenGilead SciencesBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenSangamo TherapeuticsBio-Techne